首页> 外文期刊>Molecular and Cellular Biology >Identification of a Src Tyrosine Kinase/SIAH2 E3 Ubiquitin Ligase Pathway That Regulates C/EBPδ Expression and Contributes to Transformation of Breast Tumor Cells
【24h】

Identification of a Src Tyrosine Kinase/SIAH2 E3 Ubiquitin Ligase Pathway That Regulates C/EBPδ Expression and Contributes to Transformation of Breast Tumor Cells

机译:Src酪氨酸激酶/ SIAH2 E3泛素连接酶途径的鉴定,该途径调节C /EBPδ表达并有助于乳腺癌细胞的转化

获取原文
           

摘要

The transcription factor CCAAT/enhancer-binding protein delta (C/EBPδ, CEBPD) is a tumor suppressor that is downregulated during breast cancer progression but may also promote metastasis. Here, we have investigated the mechanism(s) regulating C/EBPδ expression and its role in human breast cancer cells. We describe a novel pathway by which the tyrosine kinase Src downregulates C/EBPδ through the SIAH2 E3 ubiquitin ligase. Src phosphorylates SIAH2 in vitro and leads to tyrosine phosphorylation and activation of SIAH2 in breast tumor cell lines. SIAH2 interacts with C/EBPδ, but not C/EBPβ, and promotes its polyubiquitination and proteasomal degradation. Src/SIAH2-mediated inhibition of C/EBPδ expression supports elevated cyclin D1 levels, phosphorylation of retinoblastoma protein (Rb), motility, invasive properties, and survival of transformed cells. Pharmacological inhibition of Src family kinases by SKI-606 (bosutinib) induces C/EBPδ expression in an SIAH2-dependent manner, which is necessary for “therapeutic” responses to SKI-606 in vitro. Ectopic expression of degradation-resistant mutants of C/EBPδ, which do not interact with SIAH2 and/or cannot be polyubiquitinated, prevents full transformation of MCF-10A cells by activated Src (Src truncated at amino acid 531 [Src-531]) in vitro. These data reveal that C/EBPδ expression can be regulated at the protein level by oncogenic Src kinase signals through SIAH2, thus contributing to breast epithelial cell transformation.
机译:转录因子CCAAT /增强子结合蛋白δ(C /EBPδ,CEBPD)是一种抑癌剂,在乳腺癌进展过程中被下调,但也可能促进转移。在这里,我们研究了调节C /EBPδ表达的机制及其在人乳腺癌细胞中的作用。我们描述了一种新型途径,酪氨酸激酶Src通过SIAH2 E3泛素连接酶下调C /EBPδ。 Src在体外使SIAH2磷酸化,并导致酪氨酸磷酸化和SIAH2在乳腺癌细胞系中的活化。 SIAH2与C /EBPδ相互作用,但不与C /EBPβ相互作用,并促进其多聚泛素化和蛋白酶体降解。 Src / SIAH2介导的C /EBPδ表达抑制可提高细胞周期蛋白D1水平,视网膜母细胞瘤蛋白(Rb)的磷酸化,运动性,侵袭性和转化细胞的存活率。 SKI-606(波舒替尼)对Src家族激酶的药理抑制作用以SIAH2依赖性方式诱导C /EBPδ表达,这是对SKI-606体外“治疗”应答所必需的。不与SIAH2相互作用和/或不能被多泛素化的C /EBPδ的抗降解突变体的异位表达可防止MCF-10A细胞被活化的Src完全转化(Src截短于氨基酸531 [Src-531])。 em>体外。这些数据表明,通过SIAH2的致癌Src激酶信号可以在蛋白质水平上调节C /EBPδ的表达,从而有助于乳腺癌上皮细胞的转化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号